Synthetic polyurethane composite
Embodiments of the present inventions comprise composites of polyurethane(s), osteoconductive matrix, and, optionally, a growth factor. Embodiments further comprise methods of making such composite and uses thereof. The osteoconductive matrix can be a tricalcium phosphate, bioglass, or the like, and can include particles that are surface modified. Growth factors can be provided in powder form, including bone morphogenic proteins such as rhBMP-2. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells.
1. A composite, comprising:
a NCO-terminated prepolymer comprising a polyisocyanate that includes about 10 wt % to about 55 wt % NCO and a first polyol that includes a molecular weight of about 100 g/mol to about 1000 g/mol;
a second polyol; and
a bioceramic material;
wherein said composite is biodegradable.
2. The composite of claim 1 , further comprising a bioactive agent.
3. The composite of claim 2 , wherein the bioactive agent is at least one of an antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, protein, glycoprotein, lipoprotein, antibody, steroidal compound, antibiotic, antimycotic, cytokine, vitamin, carbohydrate, lipid, extracellular matrix, extracellular matrix component, chemotherapeutic agent, cytotoxic agent, growth factor, anti-rejection agent, analgesic, anti-inflammatory agent, viral vector, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer-cell scaffolding agent with parenchymal cells, angiogenic drug, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, and penetraction enhancer; and combinations thereof.
4. The composite of claim 3 , wherein the growth factor is recombinant human bone morphogenetic growth factor-2 (rhBMP-2).
5. The composite of claim 3 , wherein the composite comprises about 50 to about 400 μg/mL of the growth factor.
6. The composite of claim 1 , wherein the bioceramic material comprises β-tricalcium phosphate and derivatives thereof.
7. The composite of claim 6 , wherein the bioceramic material is surface-modified.
8. The composite of claim 6 , wherein the bioceramic material is surface-modified with polycaprolactone, 3-aminopropyl-triethoxysilane, or a combination thereof.
9. The composite of claim 1 , wherein the composite has a porosity of about 0% to about 80%.
10. The composite of claim 1 , wherein the composite comprises about 30 wt % to about 90 wt % bioceramic material.
11. The composite of claim 1 , wherein the bioceramic material comprises particles that range from about 1 μm to about 500 μm in diameter.
12. The composite of claim 1 , wherein the polyurethanes are degraded within approximately 4 weeks to approximately 12 months.
13. The composite of claim 1 , further comprising a catalyst.
14. The composite of claim 13 , wherein the catalyst comprises a tertiary amine.
15. The composite of claim 14 , wherein the catalyst is selected from the group consisting of bis(2-demethylaminoethyl)ether (DMAEE), triethylene diamine (TEDA), Tegoamin33, stannous octoate, dibutyltin dilaurate, and Coscat organometallic catalysts manufactured by Vertullus (a bismuth based catalyst).
16. A method of preparing a composite, comprising:
providing a composition that comprises a second polyol, a catalyst and water;
contacting the composition with a NCO-terminated prepolymer comprising a polyisocyanate that includes about 10 wt % to about 55 wt % NCO and a first polyol that includes a molecular weight of about 100 g/mol to about 1000 g/mol;
adding at least 30 wt % of a bioceramic material to the composition;
wherein said composite is biodegradable.
17. The method of claim 16 , wherein the bioceramic material comprises β-tricalcium phosphate and derivatives thereof.
18. The method of claim 16 , further comprising:
contacting the bioceramic material with a modifying substance to surface modify the bioceramic material.
19. The method of claim 18 , wherein the modifying substance is polycaprolactone, 3-aminopropyl-triethoxysilane, or a combination thereof.
20. The method of claim 16 , further comprising:
adding a bioactive agent to the composition, wherein the bioactive agent is at least one of an antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, protein, glycoprotein, lipoprotein, antibody, steroidal compound, antibiotic, antimycotic, cytokine, vitamin, carbohydrate, lipid, extracellular matrix, extracellular matrix component, chemotherapeutic agent, cytotoxic agent, growth factor, anti-rejection agent, analgesic, anti-inflammatory agent, viral vector, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer-cell scaffolding agent with parenchymal cells, angiogenic drug, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, and penetraction enhancer; and combinations thereof.
21. The method of claim 20 , wherein the growth factor is recombinant human bone morphogenetic growth factor-2 (rhBMP-2).
22. A method of treating a bone condition of a subject, comprising:
administering to a bone site a biodegradable composite including a NCO-terminated prepolymer comprising a polyisocyanate that includes about 10 wt % to about 55 wt % NCO and a first polyol that includes a molecular weight of about 100 g/mol to about 1000 g/mol, a second polyol, and a bioceramic material.
23. The method of claim 22 , wherein the bioceramic material comprises β-tricalcium phosphate and derivatives thereof.
24. The method of claim 23 , wherein the bioceramic material is surface-modified.
25. The method of claim 24 , wherein the bioceramic material surface-modified with polycaprolactone, 3-aminopropyl-triethoxysilane, or a combination thereof.
26. The method of claim 22 , wherein the composite further comprises a bioactive agent that is at least one of an antiviral agent, antimicrobial agent, antibiotic agent, amino acid, peptide, protein, glycoprotein, lipoprotein, antibody, steroidal compound, antibiotic, antimycotic, cytokine, vitamin, carbohydrate, lipid, extracellular matrix, extracellular matrix component, chemotherapeutic agent, cytotoxic agent, growth factor, anti-rejection agent, analgesic, anti-inflammatory agent, viral vector, protein synthesis co-factor, hormone, endocrine tissue, synthesizer, enzyme, polymer-cell scaffolding agent with parenchymal cells, angiogenic drug, collagen lattice, antigenic agent, cytoskeletal agent, mesenchymal stem cells, bone digester, antitumor agent, cellular attractant, fibronectin, growth hormone cellular attachment agent, immunosuppressant, nucleic acid, surface active agent, and penetraction enhancer; and combinations thereof.
27. The method of claim 23 , wherein the growth factor is recombinant human bone morphogenetic growth factor-2 (rhBMP-2).
28. The method of claim 22 , wherein the step of administering includes injecting the composite on to a bone site and allowing the composite to cure on the bone site.
29. The method of claim 22 , wherein the step of administering includes molding the composite and then placing the molded composite on to the bone site.
30. The method of claim 24 , wherein the bone site is a site on a ethmoid, frontal, nasal, occipital, parietal, temporal, mandible, maxilla, zygomatic, cervical vertebra, thoracic vertebra, lumbar vertebra, sacrum, rib, sternum, clavicle, scapula, humerus, radius, ulna, carpal bone, metacarpal bone, phalange, ilium, ischium, pubis, femur, tibia, fibula, patella, calcaneus, tarsal, or metatarsal bone.
31. The method of claim 22 , wherein the bone condition is a simple fracture, a compound fracture, a non-union, a spinal injury, scoliosis, lordosis, or kyphosis.
32. The method of claim 22 , wherein the method comprises joint reconstruction, arthrodesis, arthroplasty or cup arthroplasty of the hip, femoral or humeral head replacement, femoral head surface replacement or total joint replacement, repair of the vertebral column, spinal fusion, internal vertebral fixation, tumor surgery, deficit filling, discectomy, laminectomy, excision of a spinal tumor, anterior cervical or thoracic operation, intermaxillary fixation of a fracture, mentoplasty, temporomandibular joint replacement, alveolar ridge augmentation and reconstruction, sinus lift, a cosmetic procedure, revision surgery, or revision surgery of a total joint arthroplasty.